The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NEONAX: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer—A phase II study of the AIO Pancreatic Cancer Group.
Thomas Jens Ettrich
No relevant relationships to disclose
Andreas W. Berger
No relevant relationships to disclose
Rainer Muche
No relevant relationships to disclose
Manfred P. Lutz
No relevant relationships to disclose
Nicole Prasnikar
No relevant relationships to disclose
Waldemar Uhl
No relevant relationships to disclose
Andrea Tannapfel
No relevant relationships to disclose
Volker Heinemann
No relevant relationships to disclose
Thomas Seufferlein
No relevant relationships to disclose